JP6401292B2 - 抗ｎｍｅ抗体 - Google Patents

抗ｎｍｅ抗体 Download PDF

Info

Publication number
JP6401292B2
JP6401292B2 JP2016561611A JP2016561611A JP6401292B2 JP 6401292 B2 JP6401292 B2 JP 6401292B2 JP 2016561611 A JP2016561611 A JP 2016561611A JP 2016561611 A JP2016561611 A JP 2016561611A JP 6401292 B2 JP6401292 B2 JP 6401292B2
Authority
JP
Japan
Prior art keywords
nme7
cells
seq
cancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016561611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512825A (ja
JP2017512825A5 (enExample
Inventor
バンダッド，シンシア
スマッジ，ブノワ
Original Assignee
ミネルバ バイオテクノロジーズ コーポレーション
ミネルバ バイオテクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/050773 external-priority patent/WO2015023694A2/en
Application filed by ミネルバ バイオテクノロジーズ コーポレーション, ミネルバ バイオテクノロジーズ コーポレーション filed Critical ミネルバ バイオテクノロジーズ コーポレーション
Publication of JP2017512825A publication Critical patent/JP2017512825A/ja
Publication of JP2017512825A5 publication Critical patent/JP2017512825A5/ja
Application granted granted Critical
Publication of JP6401292B2 publication Critical patent/JP6401292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
JP2016561611A 2014-04-07 2015-04-07 抗ｎｍｅ抗体 Active JP6401292B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461976390P 2014-04-07 2014-04-07
US61/976,390 2014-04-07
USPCT/US2014/050773 2014-08-12
PCT/US2014/050773 WO2015023694A2 (en) 2013-08-12 2014-08-12 Method for enhancing tumor growth
USPCT/US2014/061821 2014-10-22
USPCT/US2014/061821 2014-10-22
US201562114526P 2015-02-10 2015-02-10
US62/114,526 2015-02-10
US201562127746P 2015-03-03 2015-03-03
US62/127,746 2015-03-03
PCT/US2015/024764 WO2015157322A2 (en) 2014-04-07 2015-04-07 Anti-nme antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018165618A Division JP6646118B2 (ja) 2014-04-07 2018-09-05 抗ｎｍｅ抗体

Publications (3)

Publication Number Publication Date
JP2017512825A JP2017512825A (ja) 2017-05-25
JP2017512825A5 JP2017512825A5 (enExample) 2017-07-06
JP6401292B2 true JP6401292B2 (ja) 2018-10-10

Family

ID=54288530

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016561611A Active JP6401292B2 (ja) 2014-04-07 2015-04-07 抗ｎｍｅ抗体
JP2018165618A Active JP6646118B2 (ja) 2014-04-07 2018-09-05 抗ｎｍｅ抗体
JP2020001446A Active JP7042854B2 (ja) 2014-04-07 2020-01-08 抗ｎｍｅ抗体
JP2022040438A Pending JP2022095648A (ja) 2014-04-07 2022-03-15 抗ｎｍｅ抗体
JP2024032381A Pending JP2024084747A (ja) 2014-04-07 2024-03-04 抗ｎｍｅ抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018165618A Active JP6646118B2 (ja) 2014-04-07 2018-09-05 抗ｎｍｅ抗体
JP2020001446A Active JP7042854B2 (ja) 2014-04-07 2020-01-08 抗ｎｍｅ抗体
JP2022040438A Pending JP2022095648A (ja) 2014-04-07 2022-03-15 抗ｎｍｅ抗体
JP2024032381A Pending JP2024084747A (ja) 2014-04-07 2024-03-04 抗ｎｍｅ抗体

Country Status (11)

Country Link
US (4) US20170204196A1 (enExample)
EP (2) EP4050103A1 (enExample)
JP (5) JP6401292B2 (enExample)
KR (2) KR20210107166A (enExample)
CN (1) CN106414726A (enExample)
AU (1) AU2015243948B2 (enExample)
CA (1) CA2945162A1 (enExample)
IL (2) IL248220A0 (enExample)
SG (2) SG11201608389RA (enExample)
TW (1) TWI746420B (enExample)
WO (1) WO2015157322A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519120A (ja) * 2019-02-04 2022-03-18 ミネルヴァ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
CA3039797A1 (en) * 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
WO2018183654A1 (en) * 2017-03-29 2018-10-04 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
IL298780A (en) * 2020-06-08 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US20050163784A1 (en) 2002-06-17 2005-07-28 Valentijn Linda J. Novel cancer therapies
EP1536814A4 (en) * 2002-07-03 2006-02-15 Immunogen Inc ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
AU2003299643A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
US20070122414A1 (en) 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
JP2010530437A (ja) 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
US8273541B2 (en) 2008-09-17 2012-09-25 Innate Pharma Compositions and methods for detecting TLR3
CN102239182B (zh) 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
US20110195089A1 (en) 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
EA026732B1 (ru) * 2009-06-11 2017-05-31 Минерва Байотекнолоджиз Корпорейшн Способы культивирования стволовых клеток и клеток-предшественников
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013059373A2 (en) 2011-10-17 2013-04-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
EP2818480B1 (en) 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
DE18200782T1 (de) * 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
CA2880010A1 (en) * 2012-07-24 2014-01-30 Minerva Biotechnologies Corporation Nme variant species expression and suppression
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
CA2886161A1 (en) 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108409862B (zh) 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
US20200165354A1 (en) 2016-09-20 2020-05-28 WuXi Biologics Ireland Limited Novel Anti-PCSK9 Antibodies
CA3039797A1 (en) 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
US20200390870A1 (en) 2017-11-27 2020-12-17 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
CN113727602B (zh) 2019-02-04 2023-10-03 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
IL298780A (en) 2020-06-08 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519120A (ja) * 2019-02-04 2022-03-18 ミネルヴァ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
JP7695193B2 (ja) 2019-02-04 2025-06-18 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法

Also Published As

Publication number Publication date
US20190031778A1 (en) 2019-01-31
CA2945162A1 (en) 2015-10-15
US20220289865A1 (en) 2022-09-15
JP2022095648A (ja) 2022-06-28
IL248220A0 (en) 2016-11-30
AU2015243948A1 (en) 2016-10-27
US20250011469A9 (en) 2025-01-09
JP7042854B2 (ja) 2022-03-28
JP2017512825A (ja) 2017-05-25
US11702483B2 (en) 2023-07-18
JP2024084747A (ja) 2024-06-25
WO2015157322A3 (en) 2015-12-23
AU2015243948B2 (en) 2020-10-15
US12479928B2 (en) 2025-11-25
EP4050103A1 (en) 2022-08-31
KR20210107166A (ko) 2021-08-31
KR102294483B1 (ko) 2021-08-27
SG10201808867PA (en) 2018-11-29
WO2015157322A2 (en) 2015-10-15
TWI746420B (zh) 2021-11-21
US20170204196A1 (en) 2017-07-20
EP3129476A2 (en) 2017-02-15
IL291164A (en) 2022-05-01
EP3129476B1 (en) 2022-01-05
CN106414726A (zh) 2017-02-15
JP2018203765A (ja) 2018-12-27
EP3129476A4 (en) 2017-11-08
TW201542595A (zh) 2015-11-16
US20190031779A1 (en) 2019-01-31
JP2020073562A (ja) 2020-05-14
SG11201608389RA (en) 2016-11-29
JP6646118B2 (ja) 2020-02-14
KR20160142372A (ko) 2016-12-12

Similar Documents

Publication Publication Date Title
JP7042854B2 (ja) 抗ｎｍｅ抗体
JP7695193B2 (ja) 抗ｎｍｅ抗体および癌または癌転移の治療方法
US12049514B2 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
US20230242678A1 (en) Anti-nme antibody and method of treating cancer or cancer metastasis
JPWO2021263227A5 (enExample)
JPWO2021252551A5 (enExample)
HK40064429B (zh) 抗nme抗体及治疗癌症或癌症转移的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180906

R150 Certificate of patent or registration of utility model

Ref document number: 6401292

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250